Study of combined therapy for cough variant asthma
Part of Immune system & allergy, Lungs & breathing clinical trials.
This trial tests whether adding a Chinese herbal formula (Liqin Zhike Formula) to standard asthma inhalers (ICS/LABA) works better for people with cough variant asthma. You may be eligible if you are newly diagnosed or have stopped asthma medication for over 3 months and still meet the criteria.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 70 years old.
- You have a chronic cough lasting more than 8 weeks, typically at night or early morning, without wheezing.
- You have a cough severity score over 5 points.
- You must have positive results from a lung function test showing reversible airflow limitation.
- You have not had a respiratory infection in the last 4 weeks.
- You are not pregnant, do not smoke, and do not take ACE inhibitor medications.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how asthma affects people in China and tries to find patterns that might help predict which treatments work best. If you have asthma and are between 18 and 75, you may be able to join.
This study looks at how traditional Chinese medicine affects people with asthma. It may help researchers understand what treatments work best for different patients.
This trial tests a traditional Chinese herbal compound formula for people with COPD. It aims to see if the herbal treatment can help improve lung health when used on top of standard inhaler therapy.
This trial tests an investigational tablet for people with chronic lung diseases like bronchiectasis, COPD, or asthma who produce at least 10 mL of sputum (mucus coughed up from the lungs) each day. The goal is to see if the drug safely reduces excess airway mucus.
This trial is testing if inhaled steroid medications (ICS or ICS/LABA) can help people whose cough continues long after a COVID-19 infection. It is designed for adults whose cough started after a positive COVID test and has lasted more than 8 weeks without other lung issues.
This trial tests an herbal medicine called NRICM102 for people with chronic cough and long-term lung diseases like asthma or COPD. It aims to see if the medicine is safe and helps improve symptoms.
Hear when a new Asthma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.